EST Vertex Pharmaceuticals (VRTX) files automatic mixed securities shelfMaximize Your Portfolio with Data Driven Insights:Leverage the ...
Ongoing launch of CASGEVY® continues to gain momentum; new cell patient collection initiations expected to significantly ...
Ongoing launch of CASGEVY ® continues to gain momentum; new cell patient collection initiations expected to significantly grow in 2025- -More than 50 authorized treatment centers (ATCs) activated ...
4d
Zacks.com on MSNVRTX's Q4 Earnings Miss Mark, Revenues Beat on Higher Product SalesVertex Pharmaceuticals Incorporated VRTX reported adjusted earnings of $3.98 per share for the fourth quarter of 2024, ...
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today reported consolidated financial results for the fourth quarter and full year ended December 31, 2024, and provided ...
We recently published a list of Jim Cramer Discussed 10 Stocks Leading the Dow Higher in 2025. In this article, we are going ...
The US Food and Drug Administration (FDA) has approved a non-opioid drug for severe post-surgical pain, which could “redefine ...
To precache or to bundle your PSOs, that is the question. Fortunately, Epic has the answer, too.
Bedgear has launched a sale on many of its temperature-regulating pillows and bedding accessories, including a luxury Glacier ...
The U.S. Food and Drug Administration approved a new prescription-strength pain reliever from Vertex Pharmaceuticals on Jan. 30, 2025. Journavx is a non-opioid drug that prevents peripheral nerves ...
Manchester United saw their recent good form grind to a half against Crystal Palace at Old Trafford. Ruben Amorim's side had won three straight games against Rangers, Fulham and FCSB to lift the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results